News Zealand Pharma A/S

Stocks

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-11 am EDT			5-day change	1st Jan Change
294.30 ^DKK	+3.85%		-9.81%	-36.90%

11:03am	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
09:27am	Wolfe Downgrades Zealand Pharma Following Weak Tolerability Data for Obesity Drug	FW

All News

Mentions Relevance

09:27am	Wolfe Downgrades Zealand Pharma Following Weak Tolerability Data for Obesity Drug	FW
Jun. 10	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	GL
Jun. 10	DNB Carnegie trims Zealand Pharma price target to DKK 425 (440), reiterates Buy	FW
Jun. 09	Zealand Pharma A/S Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
Jun. 08	Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)	GL
Jun. 08	Zealand Pharma increases its share capital as a result of the exercise of employee warrants	GL
Jun. 08	Major European indices flat - Zealand Pharma plunges	FW
Jun. 08	Zealand Pharma plunges following side effects in obesity drug trial	FW
Jun. 08	Zealand Pharma shares drop 25% after a quarter of patients quit obesity drug trial	RE
Jun. 08	Zealand Pharma partner reports robust Phase 3 obesity data	FW
Jun. 07	Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis	GL
Jun. 05	New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity	GL
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI
Jun. 03	Deutsche Bank raises Zealand Pharma price target to DKK 300 (275), reiterates Hold	FW
Jun. 02	Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference	GL
Jun. 01	Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)	GL
Jun. 01	Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons	AQ
Jun. 01	BNP Paribas raises Zealand Pharma price target to DKK 350 (275), reiterates Neutral - BN	FW
May. 29	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	GL
May. 27	Zealand Pharma to participate in the Jefferies Global Healthcare Conference	GL
May. 27	Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions	GL
May. 26	Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)	GL
May. 26	Resolutions from Zealand Pharma's Extraordinary General Meeting 2026	GL
May. 26	Zealand Pharma A/S Elects Camilla Sylvest to the Board of Directors	CI
May. 19	Gubra Appoints Adam Lange as Head of Investor Relations	AQ